Glenmark’s Ichnos drug is showing promising results for multiple myeloma, a rare blood cancer, raising hopes for affordable breakthrough therapy. With the global market for such drugs projected to reach about USD 30 billion by decade’s end, the question is whether early clinical signals can translate into scale and pricing power against global heavyweights like J&J, Gilead, and Sanofi.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
